Indicators of proliferation and invasion in ovarian tumors of low malignant potential;Invasions- und proliferationsfaktoren bei LMP-tumoren des ovars: Mogliche konsequenzen fur die klinik

Geburtshilfe und Frauenheilkunde

Volumn 59, Issue 10, 1999, Pages 507-512

  Schmalfeldt, B ^a,d   Kuhn, W ^a   Harbeck, N ^a   Spathe K ^a   Dettmar, P ^b   Berger, U ^c   Schmitt, M ^a   Graeff, H ^a  

^a Frauenklinik und Poliklinik ^*  (Germany)

^b Institut für Allgemeine Pathologie und Pathologische Anatomie   (Germany)

^c TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^d TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CYCLOPHOSPHAMIDE; DNA; PLASMINOGEN ACTIVATOR INHIBITOR 1; UROKINASE;

BENIGN TUMOR; CANCER INVASION; CELL CYCLE S PHASE; CELL PROLIFERATION; CONTROLLED STUDY; CYSTADENOMA; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALIGNANT NEOPLASTIC DISEASE; OVARY CARCINOMA; PLOIDY; PROSPECTIVE STUDY; REVIEW;

EID: 0032861416     PISSN: 00165751     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (29)

1. Lawrence, W. D.: The borderland between benign and malignant surface epithelial ovarian tumors, current controversy over the nature and nomenclature of "borderline" ovarian tumors. Cancer 76 (Suppl.) (1995) 2138-2142.
2. Trimble, C. L., E. L. Trimble: Management of epithelial tumors of low malignant potential. Gynecol. Oncol. 55 (1994) 52-61.
3. Barnhill, D. R., R. J. Kurman, M. F. Brady, G. A. Omura, E. Yordan, F. T. Given, P. R. Kucera, L. D. Roman: Preliminary analysis of the behavior of stage I ovarian serious tumors of low malignant potential: a Gynecologic Oncology Group study. J. Clin. Oncol. 13 (1995) 2752-2756.
4. Kaern, J., C. G. Tropé, V. M. Abeler: A retrospective Study of 370 Borderline Tumors of the ovary treated at the Norwegian Radium Hospital from 1970 to 1982. Cancer 71 (1993) 1810-1820.
5. Kennedy, A. W., W. R. Hart: Ovarian papillary serous tumors of low malignant potential (serous borderline tumors). A long term follow-up study, including patients with microinvasion, lymph node metastasis, and transformation to invasive serous carcinoma. Cancer 78 (1996) 278-286.
6. Bell, D. A., M. A. Weinstock, R. E. Scully: Peritoneal implants of ovarian serous borderline tumors. Histologic features and prognosis. Cancer 62 (1988) 2212-2222.
7. Kaern, J., C. G. Tropé, G. B. Kristensen, B. M. Abeler, E. O. Pettersen: DNA ploidy; the most important prognostic factor in patients with borderline tumors of the ovary. Int. J. Gynecol. Cancer 3 (1993) 349-358.
8. Zheng, J., W. F. Benedict, H. J. Xu, S. X. Hu, T. M. Kim, M. Velicescu, M. Wan, K. F. Cofer, L. Dubeau: Genetic disparity between morphologically benign cysts contiguous to ovarian carcinomas and solitary cystadenomas. J. Natl. Cancer Inst. 87 (1995) 1146-1153.
9. Liapis, H., L. M. Adler, M. R. Wick, J. S. Rader: Expression of alpha(v)beta3 integrin is less frequent in ovarian epithelial tumors of low malignant potential in contrast to ovarian carcinomas. Hum. Pathol. 28 (1997) 443-449.
10. Diebold, S. S., G. B. Baretton, B. Suchy, W. Meier, C. J. Haas, U. Lohrs: Interphase cytogenetic analysis of mucinous ovarian neoplasms. Lab. Invest. 76 (1997) 661-670.
11. Friedlander, M. L., P. Russell, I. W. Taylor, D. W. Hedley, M. H. N. Tattersall: Flow cytometric analysis of cellular DNA content as an adjunct to the diagnosis of ovarian tumors of borderline malignancy. Pathology 16 (1984) 301-306.
12. Seidman, J. D., H. J. Norris, J. L. Griffin, C. L. Hitchcock: DNA flow cytometric analysis of serous ovarian tumors of low malignant potential. Cancer 71 (1993) 3947-3951.
13. Demirel, D., R. Laucirica, A. Fishman, R. G. Ovens, M. M. Grey, A. L. Kaplan, I. Ramzy: Ovarian tumors of low malignant potential. Correlation of DNA index and S-phase fraction with histopathologic grade and clinical outcome. Cancer 77 (1996) 1494-1500.
14. Schmitt, M., N. Harbeck, C. Thomssen, O. Wilhelm, V. Magdolen, U. Reuning, K-Ulm, H. Höfler, F. Jänicke, H. Graeff: Clinical impact of the plasminogen activation system in tumor invasion and metastasis: prognostic relevance and target for therapy. Thrombosis and Hemostasis 78 (1997) 285-296.
15. Andreasen, P. A., I. Kjøller, L. Christensen, M. J. Duffy: The urokinase-type plasminogen activator system in cancer metastasis: A review. Int. J. Cancer 72 (1997) 1-22.
16. Kuhn, W., L. Pache, B. Schmalfeldt, P. Dettmar, M. Schmitt, F. Jänicke, H. Graeff: Urokinase (uPA) and PAI-1 predict survival in advanced ovarian cancer patients (FIGO III) after radical surgery and platinum based chemotherapy. Gynecol. Oncol. 55 (1994) 401-409.
17. Kuhn, W., B. Schmalfeldt, U. Reuning, L. Fache, U. Berger, K. Ulm, N. Harbeck, K. Spaethe, P. Dettmar, H. Hoefler, F. Jänicke, M. Schmitt, H. Graeff: Prognostic significance of urokinase (uPA) and its inhibitor PAI-1 for survival in advanced ovarian carcinoma stage FIGO IIIc. Brit. J. Cancer 79 (1999) 1746-1751.
18. Hedley, D. W., M. L. Friedlander, I. W. Taylor, C. A. Rugg, E. A. Musgrove: Method for analysis of cellular DNA content of paraffin-embedded pathological material using flow cytometry. J. Histochem. Cytochem. 31 (1983) 1333-1335.
19. Elchalal, U., R. Dgani, B. Piura, S. O. Anteby, Y. Zalel, B. Czernobilsky, J. G. Schenken Current concepts in management of epithelial ovarian tumors of low malignant potential. Obstet. Gynecol. Surv. 50 (1994) 62-70.
20. Leake, J. F., J. S. Rader, J. D. Woodruff, N. B. Rosenshein: Retroperitoneal lymphatic involvement with epithelial ovarian tumors of low malignant potential. Gynecol. Oncol. 42 (1991) 124-130.
21. Schmalfeldt, B., W. Kuhn, N. Harbeck, L. Pache, U. Reuning, P. Dettmar, F. Jänicke, M. Schmitt, H. Graeff: The prognostic impact of markers for invasion and proliferation in ovarian cancer. Cancer Detect. Prevent. 20 (1996) 532-533.
22. Kühn, W. M. Kaufmann, G. E. Feichter, H. H. Rummel, H. Schmid, D. Heberling: DNA flow cytometry, clinical and morphological parameters as prognostic factors for advanced malignant and borderline ovarian tumor. Gynecol. Oncol. 33 (1989) 360-367.
23. Stefansson, S., D. A. Lawrence: The serpin PAI-1 inhibits cell migration by blocking integrin alpha V beta 3 binding to vitronectin. Nature 383 (1996) 441-443.
24. Van der Burg, M. E. L., S. C. Henzen-Logmans, E. M. J. J. Berns, W. I. J. van Putten, J. G. M. Klijn, J. A. Foekens: Expression of urokinase-type plasminogen activator (uPA) and its inhibitor PAI-1 in benign, borderline, malignant primary and metastatic ovarian tumors. Int. J. Cancer 69 (1996) 475-479.
25. Gleeson, N. C., B. J. Hill, L. C. Moscinski, J. E. Mark, W. S. Roberts, M. S. Hoffman, J. V. Fiorica, D. Cavanagh: Urokinase plasminogen activator in ovarian cancer. Europ. J. Gynaecol. Oncol. 17 (1996) 110-113.
26. Garzetti, G. G., A. Ciavattini, G. Goteri: Ki-67 antigen immunostaining (MIB monoclonal antibody) in serous ovarian tumors: Index of proliferative activity with prognostic significance. Gynecol. Oncol. 56 (1995) 169-174.
27. Wan, M., W. Z. Li, B. D. Duggan, J. C. Felix, Y. Zhao, L. Dubeau: Telomerase activity in benign and malignant epithelial ovarian tumors. J. Natl. Cancer Inst. 89 (1997) 437-441.
28. Link, C. J., E. Kohn, E. Reed: The relationship between borderline ovarian tumors and epithelial ovarian carcinoma: Epidemiologic, pathologic, and molecular aspects. Gynecol. Oncol. 60 (1996) 347-354.
29. Mok, S. C.-H., D. A. Bell, R. C. Knapp: Mutation of K-ras protooncogene is associated with histologic subtype in human ovarian epithelial tumors of borderline malignancy. Cancer Res. 53 (1993) 1489-1492.